₹399.80 Crores | Listing at BSE, NSE | Mon, Oct 31, 2022 - Thu, Nov 10, 2022
Suven Life Sciences Limited Rights Issue comprises 7.27 Cr equity shares aggregating to ₹399.80 Cr, offered at an issue price of ₹55 per share with a face value of ₹1 per share.
The record date for determining eligible shareholders is Oct 18, 2022.
As per the terms of payment, ₹55 per share payable in full at the time of application.
The Rights Entitlements are expected to be credited to eligible demat accounts on Oct 28, 2022.
The Rights Issue opens on Oct 31, 2022 and closes on Nov 10, 2022.
The deemed date of allotment is Nov 18, 2022, following which the equity shares are expected to be credited to demat accounts on Nov 21, 2022 and listed on NSE and BSE on Nov 24, 2022.
Ernst & Young Merchant Banking Services LLP is the Lead Manager to the issue and Kfin Technologies Ltd. is the Registrar to the Issue.
Investors are advised to refer to the Suven Life Sciences Limited Letter of Offer for detailed information, including risk factors, issue terms, and procedural details.
Record Date
Tue, Oct 18, 2022
Entitlement Ratio
:
Open Date
Mon, Oct 31, 2022
Close Date
Thu, Nov 10, 2022
| Period Ended | Total Assets | Total Revenue | Profit After Tax |
|---|---|---|---|
| 31-Mar-21 | 128.42 | 21.23 | -72.15 |
| 31-Mar-22 | 108.03 | 17.16 | -122 |
| Amount in ₹ Crore | |||
Incorporated in 1989, Suven Life Sciences provides a wide range of Drug Discovery and Development Support Services (DDDSS) to global Pharma and Biotech companies. Suven discovery research is focused on discovering and developing new chemical entities (NCEs), which are best-in-class central nervous system therapies for the treatment of cognitive disorders, major depressive disorders, sleep disorders, psychiatric disorders, pain and inflammation, gastro-intestinal motility disorders.
The Company intends to utilize the Net Proceeds from the Issue towards the funding of the following objects:
1. Meeting costs related to pharmaceutical research & development and clinical trial for molecules in the research pipelines.
2. Repayment of an inter-corporate deposit availed by the Company.
3. General corporate purposes.
[Dilip Davda] SLSL has been in the pharmaceutical segment but has been posting losses for the reported periods of the RI documents. Based on its financial status, the issue is highly-priced. There is no harm in skipping this pricy bet despite being hovering above the RI price with some well-managed market operations. Read detail review...
Suven Life Sciences Limited
8-2-334, SDE Serene Chambers,
6th Floor Road No.5, Avenue 7, Banjara Hills,
Hyderabad – 500 034
Hyderabad, Telangana, 500034
The Suven Life Sciences Rights Issue 2022 opens on Mon, Oct 31, 2022, and closes on Thu, Nov 10, 2022.
Suven Life Sciences Rights Issue 2022 Schedule
| Last Date for credit of Rights Entitlements | Fri, Oct 28, 2022 |
| Last Date for renunciation of Rights Entitlements | Thu, Nov 3, 2022 |
| Issue Opening Date | Mon, Oct 31, 2022 |
| Issue Closing Date | Thu, Nov 10, 2022 |
| Date of Allotment (on or about) | Fri, Nov 18, 2022 |
| Date of Credit (on or about) | Mon, Nov 21, 2022 |
| Date of Listing (on or about) | Thu, Nov 24, 2022 |
You can apply for Suven Life Sciences Rights Issue 2022 in two ways:
Steps to apply for Suven Life Sciences Rights Issue 2022 using Net Banking (ASBA)
Steps to apply for Suven Life Sciences Rights Issue 2022 using Registrar's website (R-WAP)
